Migraine and the Excessive Dispensation of Triptans: A Real-World Evidence Study of Colombian Patients
Authors:
- Luis Fernando Valladales-RestrepoLVLuis Fernando Valladales-Restrepo
- Catalina Díaz-ArteagaCDCatalina Díaz-Arteaga
- Luis Fernando Navarrete-SantaLNLuis Fernando Navarrete-Santa
- Melba Jasbleidy Santander-PaiMSMelba Jasbleidy Santander-Pai
- José Manuel Zapata-OrozcoJZJosé Manuel Zapata-Orozco
- Guisela Villa-ArroyaveGVGuisela Villa-Arroyave
- Jorge Enrique Machado-AlbaJorge Enrique Machado-Alba
Open Access
- 26 January 2026
- journal article
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (1) , 46355
Abstract
Background: The aim of this study was to determine the use and safety of triptans in a group of patients with migraine who had excessive dispensings of antimigraine drugs. Methods: This was a cross-sectional study of patients with excessive dispensings of triptans identified by a pharmaceutical manager. The DrugBank database was used to determine rational amounts of triptans. Results: A total of 9147 patients used triptans, 44.6% of whom received excessive dispensings. A sample of 355 patients was selected, 22.8% of whom received regular doses of triptans daily. Adverse events were common (41.1%), and some patients experienced chronic headache (32.4%) and medication-overuse headache (MOH) (8.2%). Increasing age [adjusted odds ratio (aOR): 1.042; 95% confidence interval (CI): 1.008–1.077], a history of migraine for more than 10 years (aOR: 3.73; 95% CI: 1.37–10.16), previous dispensings of simple analgesics (aOR: 2.463; 95% CI: 1.001–6.057), and concomitant psychiatric illnesses (aOR: 3.583; 95% CI: 1.452–8.844) were associated with a higher probability of MOH. Conclusions: In this study conducted in a middle- to low-income Latin American country, triptans were commonly dispensed for patients with migraine, and their dosage did not comply with the recommendations of clinical practice guidelines for some patients. Increasing age, history of migraine ≥10 years, previous use of simple analgesics, and the presence of concomitant psychiatric disorders were associated with a higher probability of MOH. These findings reflect prescribing and dispensing patterns within the studied health-care context and may not fully represent the use of over-the-counter triptans or practices in other settings.Keywords
This publication has 37 references indexed in Scilit:
- Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatmentPain Management, 2025
- Educational interventions and their effects on healthcare professionals’ digital competence development: A systematic reviewInternational Journal of Medical Informatics, 2024
- DrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Research, 2023
- Medication overuse headacheNature Reviews Disease Primers, 2023
- Diagnosis and management of migraine in ten stepsNature Reviews Neurology, 2021
- MigraineNew England Journal of Medicine, 2020
- Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Neurology, 2017
- Medication-overuse headache: risk factors, pathophysiology and managementNature Reviews Neurology, 2016
- Utilización de ergotamina: ¿saben los médicos en Colombia cómo prescribirla?Neurología, 2014
- Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trøndelag Health StudiesPain, 2012